Due to the strong dependency of breast tumor development on the estrogen-estrogen receptor (ER) axis, estrogen suppression therapy and ER antagonists are the main treatments for hormone receptor-positive HER2-negative (HR+HER2-) metastatic breast cancer (MBC) (3). The gene discussed is ESR1; the disease is breast neoplasm.